PTC Therapeutics (PTCT) Misses Q3 EPS by 66c, Revenues Miss; Lowers FY18 Revenue Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. S
10. COF

Go back to PTC Therapeutics (PTCT) Misses Q3 EPS by 66c, Revenues Miss; Lowers FY18 Revenue Outlook

PTC Therapeutics Reports Third Quarter 2018 Financial Results and Provides a Corporate Update

November 5, 2018 4:01 PM EST

SOUTH PLAINFIELD, N.J., Nov. 5, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ending September 30, 2018.

"We have been aggressively pursuing our vision to build a leading, fully integrated, multiplatform biotech company," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "The addition of gene therapy aligns with our goal of developing treatments for more patients with rare disorders and the in-licensing of Tegsedi and Waylivra leverages our commercial expertise. Over the last 20 years,... More